Gamma Biosciences invests in Nirrin Technologies

By The Science Advisory Board staff writers

Gamma Biosciences has made an investment in bioprocessing firm Nirrin Technologies. Terms of the investment were not disclosed.

Gamma will provide support to Nirrin for helping expand customer engagement with the developer and manufacturers of cell and gene therapies, biologics, and vaccines, the company said.

Nirrin's bioprocessing platform uses near-infrared spectroscopy and back-end data processing for applications such as real-time glucose monitoring, cell density in-line measurements, and protein concentration and aggregation, according to Gamma Biosciences.


Copyright © 2021 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?